AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy seeking lower drug prices for Americans, a senior company executive said on Monday.
Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant, the latest in a series of setbacks this year that have fuelled concerns about the drugmaker's pipeline.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reported better second-quarter earnings than expected as growth in oncology and rare diseases helped offset weaker sales elsewhere. Total revenue increased 9% to $30.7 billion in the first half of 2026, or 6% at constant exchange rates.
The U.K. drugmaker's revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.
AstraZeneca topped second-quarter profit expectations and backed its 2026 forecasts on Monday on demand for its cancer and heart disease therapies, as the drugmaker sought to quell concerns over longer-term growth prospects after a recent trial failure.
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants digested the latest jobs, inflation, and retail sales data for July, all of which could influence the Bank of England's next policy decision.